Patient with advanced or metastatic solid tumor and has disease progression after treatment with available therapies that are known to confer clinical benefit or who are intolerant to treatment that meets the following requirements for the part of the study they will participate in:
Patients enrolled in Cohorts -, Cohort A, Cohort B and Phase  Doublet must be refractory to all therapies known to confer clinical benefit to their disease.
Diagnosis of advanced/metastatic solid malignancy for which no standard treatment option exists that will confer clinical benefit
Must have one of the following cancers, for which the patient has either received or been intolerant to all therapy known to confer clinical benefit
Participants in all monotherapy arms must have an advanced solid tumor that has progressed on standard therapies known to provide clinical benefit or the participants are intolerant to such therapies.
Participants must have an advanced solid tumor that has progressed on standard therapies known to provide clinical benefit or the participants are intolerant to such therapies.
For all parts: The participant must be, in the judgment of the investigator, an appropriate candidate for experimental therapy after available standard therapies have failed to provide clinical benefit for their advanced or metastatic cancer.
For Part A exclusively (RO monotherapy), confirmed advanced and/or metastatic solid tumor, with at least one tumor lesion of location accessible to biopsy per clinical judgment of the treating physician, and confirmed progression at baseline; for whom no standard therapy that would confer clinical benefit to the participant exists
Expectation by the investigator that the participant may continue to benefit from additional single-agent trastuzumab emtansine or combination trastuzumab emtansine treatment or Expectation of the investigator that the participant may continue to benefit from control arm treatment as given in study BO/TDMg and at the time of disease progression may benefit from single-agent trastuzumab emtansine treatment
Subjects with advanced solid tumors who are refractory to or intolerant of established therapy known to provide clinical benefit for their condition (i.e., subjects must not be candidates for regimens known to provide clinical benefit).
At least one line of prior combination and no other standard therapy with proven clinical benefit is available.
Must have received at least one prior line chemotherapy regimen and no other standard therapy with proven clinical benefit is available.
Histologically or cytologically confirmed advanced TNBC that is relapsed, refractory, or progressive and not eligible for another standard therapy that would confer clinical benefit to the subject.
EXPANDED ACCESS COHORT: Participants must be experiencing clinical benefit from the - study drug combination as judged by the treating investigator
Subjects must be refractory to or intolerant of existing cancer therapy(ies) known to provide clinical benefit.
Treatment with targeted agents, immunotherapy, or hormones is allowed; patients are only eligible if they have received and failed, or have been intolerant to standard treatments known to confer clinical benefit
Cohort A: Patients with TNBC must have received no more than  lines of systemic cytotoxic chemotherapy; patients must have received and failed, or have been intolerant to anthracycline, taxanes, capecitabine, eribulin or other agents known to confer clinical benefit; patients are not required to fail all these agents if, in the investigators opinion, patients would benefit from treatment on current protocol
HER-expressing cancer as follows: Part : Any locally advanced (unresectable) and/or metastatic HER-expressing (HER +, +, or + by IHC) cancer that has progressed after receipt of all therapies known to confer clinical benefit
HER-overexpressing (+ by IHC) or HER + and FISH positive gastric cancer must have progressed after prior treatment with trastuzumab Part : ? Locally advanced (unresectable) and/or metastatic cancer that has progressed after receipt of all therapies know to confer clinical benefit (unless ineligible to receive a specific therapy) as follows:
Has demonstrated clinical benefit from treatment with tazemetostat.
Patients must be refractory to, or not a candidate for, established therapy known to provide clinical benefit for their malignancy.
Patients with incurable malignancies, irrespective of -year mortality, who, in the opinion of the investigator have no treatment option expected to yield significant clinical benefit
PART I: Recurrent or progressive disease on prior standard therapies with known clinical benefit with the exception of adjuvant bladder cancer population
For the dose escalation portion of the trial, patients with available therapies known to confer clinical benefit (platinum sensitive ovarian cancer) must be excluded
Patients with available therapies known to confer clinical benefit (platinum sensitive\r\nrecurrent ovarian cancer) must be excluded from the dose escalation portion
Received at least one systemic therapy for advanced disease, with no further approved treatment options that provide proven clinical benefit.
Refractory to or intolerant of existing therapy(ies) known to provide clinical benefit.
Patients with metastatic bone sarcomas who have failed all available therapies that have demonstrated clinical benefit. Available therapies include but not limited to methotrexate, adriamycin and cisplatin for osteosarcoma and vincristine, adriamycin and cytoxan, ifosfamide, etoposide (VAC/IE) for Ewings sarcoma
Histologically or cytologically confirmed advanced/metastatic solid tumor and refractory to or intolerant of existing therapy(ies) known to provide clinical benefit for the condition of the participant
Patients demonstrating disease progression after treatment with available therapies that are known to confer clinical benefit, or who are intolerant to treatment,
In the opinion of the Investigator would benefit from continued treatment.
Patients must have exhausted all available therapies known to provide clinical benefit and has progressed, relapsed or is refractory to last line of treatment
Refractory to or intolerant of existing therapy(ies) known to provide clinical benefit.
Subjects with histologically or cytologically proven advanced or metastatic solid malignancies for whom no effective standard therapy exists or has failed or subjects who are intolerant to established therapy known to provide clinical benefit for their condition (dose escalation cohorts; Part I).
Subjects must have histologically confirmed malignancy that is metastatic or unresectable and for which there is no available therapy likely to convey clinical benefit.
For all arms except Arm G, subjects must be refractory to, or intolerant of, established therapy known to provide clinical benefit for their conditions, or where subjects refuse existing therapies. For Arm G, subjects must have newly histologically or cytologically confirmed diagnosis of locally advanced cervical cancer confined to the pelvis only.
Patients who have received and failed, or have been intolerant to, standard first line therapies known to confer clinical benefit; patients who refuse standard therapy would also be eligible, as long as their refusal is documented
Subjects with advanced or metastatic solid tumors that are refractory to standard therapies known to provide clinical benefit. Subjects with hematologic malignancy including lymphoma/myeloma will not be enrolled on this study.
Disease not amenable to curative intent treatment (primarily surgery) and in addition has shown either clinical or radiographic progression on all available therapies known to confer clinical benefit
Has B-cell lymphoma refractory to or intolerant of established therapy known to provide clinical benefit for their condition and having received rituximab as a single agent or in combination with other therapies.
Patient has not received available therapies that confer clinical benefit
a. Have advanced solid tumors that are refractory to established therapies known to provide clinical benefit for the malignancy in question, OR
b. Be intolerant of established therapies known to provide clinical benefit for the malignancy in question
Part : Subjects with HNSCC, NSCLC, pancreatic ductal adenocarcinoma, salivary gland cancer, and transitional cell carcinoma of the genitourinary tract that have had disease progression after available therapies for advanced or metastatic disease that are known to confer clinical benefit, have been intolerant to treatment, or have refused standard treatment.
Patients demonstrating disease progression after treatment with approved therapies that are known to confer life-prolonging benefit, or who are intolerant to or have declined treatment
Refractory to or intolerant of existing therapy(ies) known to provide clinical benefit.
Patients must be refractory to, or intolerant of, existing therapies known to provide clinical benefit for their condition (i.e., cancer diagnosis).
For dose-escalation portion of study, patients must be refractory to or intolerant of existing therapies known to provide clinical benefit for their condition.
No other therapy with demonstrated clinical benefit in relapsed/refractory B-cell NHL available to the patient
Patients must have advanced/metastatic solid malignancy or lymphoma for which no standard treatment option exists that will confer clinical benefit
Response to first infusions:\r\n* Subjects who had a PR, or SD with clinical benefit may elect to receive a second infusion of cells; subjects that initially had a CR may only receive a second dose if evaluable disease recurs; clinical benefit is indicated by an improvement in the subjects health status (eg, improved performance status or quality of life, decreased pain, etc.)
For Part  and , subjects must have progressed following at least  line of prior therapy and there is no further established therapy that is known to provide clinical benefit (including subjects who are intolerant to the established therapy)
Patients must have the potential for benefit from local therapy (at the discretion of the investigator)
Phase I (Cohorts A through D, G, H, T, T and X): Histologically documented, locally advanced or metastatic solid malignancy or NHL that has progressed or failed to respond to at least one prior regimen and are not candidates for regimens known to provide clinical benefit
Part : *Note: Subjects must have failed available therapies that are known to confer clinical benefit as indicated below, unless they are ineligible, intolerant, or refused standard treatment.
Metastatic (Stage IV) or recurrent NSCLC (according to American Joint Committee on Cancer th edition guidelines) who have had disease progression after available therapies for advanced or metastatic disease that are known to confer clinical benefit, been intolerant to treatment, or refused standard treatment.
Stage IV MSS CRC (according to American Joint Committee on Cancer th edition guidelines) who have had disease progression after available therapies for advanced or metastatic disease that are known to confer clinical benefit, been intolerant to treatment, or refused standard treatment.
For all parts: The participant must be, in the judgment of the investigator, an appropriate candidate for experimental therapy after available standard therapies have failed to provide clinical benefit for their advanced or metastatic cancer.
Patient is currently deriving clinical benefit from the study treatment, as determined by the investigator.
are, in the judgment of the investigator, appropriate candidates for experimental therapy after available standard therapies have failed to provide clinical benefit
Patients should not be eligible or able to receive approved therapy of confirmed clinical benefit in this patient population
Histological or cytological confirmation of advanced unresectable solid tumors, including those subjects who have progressed on standard anticancer therapy and for whom no further therapy that confers clinical benefit is available.
Patients enrolled in the dose escalation stages must have disease that is resistant to or relapsed following available standard systemic therapy, or for which there is no standard systemic therapy or reasonable therapy in the physician's judgment likely to result in clinical benefit or if such therapy has been refused by the patient. Documentation of the reason must be provided for patients who have not received a standard therapy likely to result in clinical benefit.
Have a tumor genomic profile for which single agent treatment with one of the FDA approved targeted anti-cancer drugs included in this study has potential clinical benefit based on the criteria described in protocol
In the opinion of the investigator would benefit from systemic therapy
Patients with a history of clinical benefit from prior RAF inhibitor therapy, as judged by the investigator, will be allowed
For all Parts (Dose escalation and expansion): The participant must be, in the judgment of the investigator, an appropriate candidate for experimental therapy either after available standard therapies have ceased to provide clinical benefit (Parts A, B, C, D, E and F) or in combination with fulvestrant (Part G only)
Advanced solid tumor for which, in the opinion of the Investigator, no other standard or investigational therapy offers greater benefit.
Refractory to or intolerant of existing therapy(ies) known to provide clinical benefit for their condition.
Subjects must have no alternate therapy of proven benefit or have refused standard therapy.
Histologically or cytologically confirmed B-cell NHL that has relapsed from, or is refractory to, standard therapies (including autologous transplantation) known to provide clinical benefit, but have not been treated with bendamustine for their lymphoma\r\n* Patients with limited exposure to Bendamustine (less than  full cycles) may be included, based on Principal Investigator (PI) discretion
Documented clinical benefit following th cycle of DI-Leu-IL.
Patients must have no available approved therapies that confer clinical benefit
Subject must have advanced and/or metastatic, histologically or cytologically documented cancer or lymphomas, for whom there is no available standard therapy shown to provide clinical benefit.
Failed available therapy known to confer clinical benefit but no more than  prior lines of chemotherapy for metastatic disease.
Absence of available therapy with reasonable likelihood of cure or significant clinical benefit
Malignancies that are refractory to or intolerant of established therapy known to provide clinical benefit. Patients must not be candidates for anti-tumor regimes known to provide clinical benefit.
Has any other clinically important abnormalities such that risk to patient of participation outweighs the potential benefit of therapy as determined by the investigator
Subject should be deriving clinical benefit without any persistent intolerable toxicity from continued treatment of ASP.
Subjects not receiving clinical benefit from previous study therapy
Previous bowel resection which, in the opinion of the investigator, would decrease the benefit of the probiotic; patients who have undergone recent bowel surgeries which would not decrease the benefit of the probiotic are eligible provided they are more than  days from surgery with no serious complications
Advanced malignancy that is relapsed and/or refractory to all available therapies that will confer clinical benefit. Newly diagnosed patients who refuse standard treatment regimens are also eligible
Rollover Cohort: Patients on active HuF-G therapy on the Phase  AML (SCI-CD-) trial who are deriving clinical benefit by Investigator assessment
Subjects who have disease progression after treatment with available therapies that are known to confer clinical benefit, or who are intolerant to treatment, or who refuse standard treatment. There is no limit to the number of prior treatment regimens.
Subjects who have disease progression after treatment with available therapies that are known to confer clinical benefit, or who are intolerant to treatment, or subjects who refuse standard treatment
